Purple biotech's randomized phase 2 cm24 pancreatic cancer study selected as late-breaking abstract poster presentation at asco 2024 annual meeting

Interim data suggests reduced risk of progression or death in the cm24/nivolumab plus standard of care nal-iri/5fu/lv arm of the study

PPBT Ratings Summary

PPBT Quant Ranking